Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Development of digital and interactive methods to teach immunology

    SBC: FLUID CONTENT INC            Topic: NIGMS

    Abstract The goal of this project is to develop a digital media based program to teach high school student about immunologyWe will develop an interactive digital media to teach minority studentshigh schoolon the introduction of immunology and compare the efficacy of learning between traditional teaching and interactive mediaWe will develop three curriculums to teach group of high school students r ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Measuring toxicant effects on cellular function in a microarray format

    SBC: CIENCIA INC            Topic: 113

    Project Summary AbstractThe EPA maintains a Toxics Release Inventory of andgttoxic chemicals that are disposed or released from andgtindustrial sites in the United Stateswhile HHS and USDA maintain a list of overselect agents and toxicants that pose a severe risk to humananimaland plant healthThese compounds represent only a fraction of the known and unknown environmental toxicants that may advers ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Noninvasive Home Assessment of Cardiac Filling Pressure to Identify Heart Failure Patients at High Risk for Readmission

    SBC: Vixiar Medical, Inc            Topic: NHLBI

    Congestive heart failureCHFis the most common reason for hospitalization in the U Swith overmillion admissions per yearPatients admitted with CHF usually need IV diuretics to promote fluid removalThe readmission rate is highoverbydaysandbydays post dischargeThis also presents an enormous economic burdenhospitalizations account for a large percentage of the $billion spent yearly on heart failureOne ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Medications for Synthetic Cannabinoid Abuse

    SBC: PAFOSPharma, LLC            Topic: R41

    PROJECT SUMMARY ABSTRACT In response to PAthis Phase I STTR proposal will aim at developing pharmacotherapies that can act aslife savermedications to counteract the neurotoxic effects of synthetic cannabinoidsSCsTowards this goalwe will synthesize CB R antagonists with fast onsets of action that can be administered in an emergency roomERsituationThe rationale is based on the successful soft agonis ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy

    SBC: Regulonix            Topic: 101

    Summary Abstract Chemotherapy induced peripheral neuropathyCIPNis detected inof cancer patients during all phases of cancerSensory symptoms in the hands and or feettypically in astocking glovepatternare commonand manifested as painnumbnessand or tinglingCIPN can result in chemotherapy dose reduction or discontinuationand can also have long term effects on the quality of lifeThe course of CIPN can ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds

    SBC: Initos Pharmaceuticals LLC            Topic: NCATS

    ABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen

    SBC: Arrevus, Inc.            Topic: NIAID

    Multi drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1

    SBC: L2 DIAGNOSTICS, LLC            Topic: NIAID

    PROJECT SUMMARYZika virusan emerging flavivirusis associated with severe clinical outcomesincluding Guillain Barrsyndrome and birth defectsTransmission of Zika virus is primarily mosquitoborneMosquito salivary proteins are known to enhance infectivity and pathogenesis in Zikadengue and West Nile viruses by modulating immune responsesThis proposal seeks to develop a novel vaccine against Zika virus ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Mechanical generation of peri-valvular oscillatory flow to prevent deep venous thrombosis.

    SBC: OsciFlex LLC            Topic: NHLBI

    Project SummaryDeep venous thrombosisDVTand secondary pulmonary embolismPEaffectof the population and cause approximatelydeaths annually in the USImmobility and lack of muscular activity is the primary risk factor for DVTan effect attributed to reduced venous flowAutopsy studies have identified the venous valve sinus in the leg as the site of origin for DVTbut a molecular and cellular mechanism fo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Novel and potent SHIP1 inhibitors for improving hematologic recovery following myelosuppressive therapies

    SBC: Alterna Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT Despite recent advances in targeting cancer cellschemotherapy remains a mainstay of oncologyextending survival and providing cures for many types of cancerHoweverchemotherapy that ablates or suppresses bone marrow cells can be debilitating even when combined with autologous hematopoietic stem cell transplantationHSCTThe treatment causes severe side effects such as anemianeutropenia and th ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government